^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L861Q

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    16h
    Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2029 --> Jun 2030 | Initiation date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2028 --> Jun 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    EGFR mutation • EGFR L861Q • EGFR G719X
    |
    carboplatin • pemetrexed • zipalertinib (CLN-081)
    6d
    Adjuvant icotinib and osimertinib in the treatment of EGFR-mutated resectable non-small cell lung cancer: A real-world multicenter cohort study in China (ChiCTR2500112843)
    P=N/A, N=200, Not yet recruiting, Beijing Chest Hospital Capital Medical University; Beijing Chest Hospital Capital Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • Conmana (icotinib) • simmitinib (SYHA1817)
    6d
    A prospective clinical study on the efficacy and safety of Limerinib Tablets in the treatment of local advanced or recurrent metastasis of EGFR mutation with meningeal metastasis and non-scaly NSCLC (ChiCTR2500111717)
    P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    6d
    Limertinib Plus Platinum-Based Chemotherapy in Patients with Advanced EGFR-Mutated Non-Squamous NSCLC after Progression on First-Line EGFR-TKI Therapy : A Single-Arm, Multicenter Study (ChiCTR2500114831)
    P2, N=61, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New P2 trial
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • pemetrexed • limertinib (ASK120067)
    6d
    A prospective single-arm phase II clinical trial on the sacituzumab tirumotecan treatment of targeted therapy pre-treated, advanced or metastatic non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500114453)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Jiataile (sacituzumab tirumotecan)
    6d
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutations (ChiCTR2500112428)
    P1, N=36, Not yet recruiting, Shanghai East Hospital; Jing Medicine Technology (Shanghai) Co., Ltd.
    New P1 trial
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion • EGFR expression • EGFR L861Q • EGFR S768I • EGFR positive
    6d
    Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-B01D1 for Injection in Patients with Locally Advanced or Metastatic Solid Tumors (ChiCTR2500113663)
    P1, N=500, Not yet recruiting, Sun Yat-sen University Cancer Center; Sichuan Baili Pharmaceutical Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • EGFR L861Q • RET mutation • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • NTRK fusion
    |
    izalontamab brengitecan (BL-B01D1)
    6d
    A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (ChiCTR2500113951)
    P1, N=258, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P1 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    9d
    Detecting EGFR Gene Mutations on a Nanobioarray Chip. (PubMed, Biomedicines)
    The gold nanoparticle-assisted wash method has enhanced differentiation between WT and mutated sequences relevant to the EGFR sensitivity to tyrosine kinase inhibitors. The WT and mutated sequences (T790M, L858R and L861Q) in genomic samples were successfully differentiated from each other.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q
    9d
    Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR Mutations. (PubMed, Cancers (Basel))
    The role and the integration of therapies targeting exon20ins or uncommon mutations into the first- and second-line treatment armamentarium for NSCLC patients is not yet fully established, and the therapeutic impact of monotherapies (e.g., sunvozertinib, firmonertinib) versus combinations with standard platinum-based chemotherapy (e.g., zipalertinib, amivantamab) currently still lacks robust evidence to further change the therapeutic landscape for these patients. Therefore, results from the ongoing trials are eagerly awaited and are expected to shed some light on these open questions.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Ivesa (firmonertinib) • Zegfrovy (sunvozertinib) • zipalertinib (CLN-081)
    11d
    Balise: A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (clinicaltrials.gov)
    P2, N=168, Completed, Eli Lilly and Company | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
    |
    erlotinib • emibetuzumab (LY2875358)
    23d
    KANNON-5: Andamertinib as First-line Treatment for NSCLC With EGFR PACC or EGFR L861Q Mutation (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Avistone Biotechnology Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q
    |
    andamertinib (PLB1004)